omniture
深圳市亦诺微医药科技有限公司 Immvira Co. Ltd

Latest News

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

  SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical T...

2021-06-12 11:16 3191

ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021

SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from its clinical Phase ...

2021-06-02 16:14 1265

AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration

SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical...

2021-04-20 08:30 1655

ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting

SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be pre...

2021-04-08 20:47 2397

ImmVira Announces Series C Financing with Leading Specialist Investors

SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnolo...

2020-12-31 19:29 3706

ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital

SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company...

2020-09-24 00:09 2171

ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies

SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceut...

2020-08-06 23:49 9544

Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer

SHENZHEN, China, June 30, 2020 /PRNewswire/ -- Today Immvira Group Company (Immvira or the "Company...

2020-07-01 08:30 2075
12